Chronic obstructive pulmonary disease (COPD) is a leading cause of death and disability
internationally. Alveolar hypoxia and consequent hypoxemia increase in prevalence as …

Obstructive sleep apnea (OSA) is probably the most common respiratory disorder, with recent
data from the United States and Europe suggesting that between 14% and 49% of middle-…

Background Benralizumab is an IL5-receptor monoclonal antibody licensed for the treatment
of severe eosinophilic asthma (SEA). It has demonstrated efficacy in clinical trials in …

… Author links open overlay panel Brian D. Kent MBBCh a , Ludger Grote PhD b , Silke Ryan
PhD a , Jean-Louis Pépin PhD c , Maria R. Bonsignore PhD d , Ruzena Tkacova PhD e , …

Background Mepolizumab was the first licensed anti-IL5 monoclonal antibody for severe
eosinophilic asthma (SEA). To date there are few data to confirm its efficacy in the real-world …

Obstructive sleep apnoea syndrome (OSAS) is a highly prevalent disease and associated with
cardiovascular morbidity and mortality. The pathogenesis of cardiovascular complications …

Obstructive sleep apnoea (OSA) is a highly prevalent disorder, which conveys an increased
risk of cardiovascular disease and death. Type 2 diabetes mellitus (T2DM), glucose …

Obstructive sleep apnoea (OSA) is increasingly associated with insulin resistance. The
underlying pathophysiology remains unclear but intermittent hypoxia (IH)-mediated inflammation …

Asthma is extremely common with a prevalence of approximately 10% in Europe. It presents
with symptoms which have a broad differential diagnosis and examination can be entirely …

Background The evidence base for the treatment of mild obstructive sleep apnoea is limited
and definitions of disease severity vary. The MERGE trial investigated the clinical …